|
1
|
Carr A, Hewlett S, Hughes R, Mitchell H,
Ryan S, Carr M and Kirwan J: Rheumatology outcomes: The patient's
perspective. J Rheumatol. 30:880–883. 2003.PubMed/NCBI
|
|
2
|
Furst DE and Emer P: Rheumatoid arthritis
pathophysiology: Update on emerging cytokine and
cytokine-associated cell targets. Rheumatology. 53:1560–1569. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dougados M, van der Heijde D, Chen YC,
Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I,
Gaich C, et al: Baricitinib in patients with inadequate response or
intolerance to conventional synthetic DMARDs: Results from the
RA-BUILD study. Ann Rheum Dis. 76:88–95. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kubo S, Nakayamada S and Tanaka Y:
Baricitinib for the treatment of rheumatoid arthritis. Expert Rev
Clin Immunol. 12:911–919. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iwata S and Tanaka Y: Progress in
understanding the safety and efficacy of Janus kinase inhibitors
for treatment of rheumatoid arthritis. Expert Rev Clin Immunol.
12:1047–1057. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fridman JS, Scherle PA, Collins R, Burn
TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, et
al: Selective inhibition of JAK1 and JAK2 is efficacious in rodent
models of arthritis: Preclinical characterization of INCB028050. J
Immunol. 184:5298–5307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi JG, Chen X, Lee F, Emm T, Scherle PA,
Lo Y, Punwani N, Williams WV and Yeleswaram S: The
pharmacokinetics, pharmacodynamics, and safety of baricitinib, an
oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol.
54:1354–1361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kubo S, Nakayamada S, Nakano K and Tanaka
Y: THU0203 baricitinib targets the type I IFN/STAT-medicated
activities of human T cells and dendritic cells. Ann Rheum Dis. 75
Suppl 2:S2602016. View Article : Google Scholar
|
|
10
|
Emery P, Mcinnes I, Genovese MC, Smolen
JS, Kremer J, Dougados M, Schlichting DE, Rooney T, Issa M, Bono
Sd, et al: A7.16 Characterisation of changes in lymphocyte subsets
in baricitinib-treated patients with rheumatoid arthritis in two
phase 3 studies. Ann Rheum Dis. 75 Suppl 1:A622016. View Article : Google Scholar
|
|
11
|
Song GG, Bae SC and Lee YH: Efficacy and
safety of tofacitinib for active rheumatoid arthritis with an
inadequate response to methotrexate or disease-modifying
antirheumatic drugs: A meta-analysis of randomized controlled
trials. Korean J Intern Med. 29:656–663. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meyer DM, Jesson MI, Li X, Elrick MM,
Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK,
Hirsch JL, et al: Anti-inflammatory activity and neutrophil
reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat
adjuvant-induced arthritis. J Inflamm (Lond). 7:412010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group, : Preferred reporting items for systematic
reviews and meta-analyses: The PRISMA statement. PLoS Med.
6:e10000972009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Felson DT, Anderson JJ, Boers M,
Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus
H, Strand V, et al: American College of Rheumatology. Preliminary
definition of improvement in rheumatoid arthritis. Arthritis Rheum.
38:727–735. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aletaha D and Smolen J: The Simplified
Disease Activity Index (SDAI) and the Clinical Disease Activity
Index (CDAI): A review of their usefulness and validity in
rheumatoid arthritis. Clin Exp Rheumatol. 23 5 Suppl 39:S100–S108.
2005.PubMed/NCBI
|
|
16
|
van Tuyl LH and Boers M: Patient's global
assessment of disease activity: What are we measuring? Arthritis
Rheum. 64:2811–2813. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bruce B and Fries JF: The Health
Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 23 Suppl
39:S14–S18. 2005.PubMed/NCBI
|
|
18
|
Higgins JP and Green S: Cochrane handbook
for systematic reviews of interventions version 5.1.0.
Naunyn-Schmiedebergs Archiv Für Exp Pathol und Pharmakol.
5:S382011.
|
|
19
|
Fleischmann R, Schiff M, van der Heijde D,
Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S,
Dickson C, de Bono S, et al: Baricitinib, methotrexate, or
combination in patients with rheumatoid arthritis and no or limited
prior disease-modifying antirheumatic drug treatment. Arthritis
Rheumatol. 69:506–517. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tanaka Y, Ishii T, Cai Z, Schlichting D,
Rooney T and Macias W: Efficacy and safety of baricitinib in
Japanese patients with active rheumatoid arthritis: A 52-week,
randomized, single-blind, extension study. Mod Rheumatol. 28:20–29.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takeuchi T, Genovese M, Xie L, Issa M,
Pinto Correia AL, Rooney T, Emoto K and Smolen J: OP0228
baricitinib dose step-down following disease control in patients
with rheumatoid arthritis. Ann Rheumat Dis:. 75 Suppl 2:144.1–144.
2016. View Article : Google Scholar
|
|
22
|
Keystone EC, Genovese MC, Schlichting DE,
de la Torre I, Beattie SD, Rooney TP and Taylor PC: Safety and
efficacy of baricitinib through 128 weeks in an open-label,
longterm extension study in patients with rheumatoid arthritis. J
Rheumatol. 45:14–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kremer JM, Genovese MC, Keystone E, Taylor
PC, Zuckerman SH, Ruotolo G, Schlichting DE, Crotzer VL, Nantz E,
Beattie SD and Macias WL: Effects of baricitinib on lipid,
apolipoprotein, and lipoprotein particle profiles in a phase iib
study of patients with active rheumatoid arthritis. Arthritis
Rheumatol. 69:943–952. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Genovese MC, Kremer J, Zamani O, Ludivico
C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP,
et al: Baricitinib in patients with refractory rheumatoid
arthritis. N Engl J Med. 374:1243–1252. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Keystone EC, Taylor PC, Drescher E,
Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK,
Luchi ME, Rooney TP, et al: Safety and efficacy of baricitinib at
24 weeks in patients with rheumatoid arthritis who have had an
inadequate response to methotrexate. Ann Rheum Dis. 74:333–340.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Emery P, Blanco R, Maldonado Cocco J, Chen
YC, Gaich CL, DeLozier AM, de Bono S, Liu J, Rooney T, Chang CH and
Dougados M: Patient-reported outcomes from a phase III study of
baricitinib in patients with conventional synthetic
DMARD-refractory rheumatoid arthritis. RMD Open. 3:e0004102017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Taylor PC, Keystone EC, van der Heijde D,
Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S,
Ishii T, Emoto K, Beattie S, et al: Baricitinib versus placebo or
adalimumab in rheumatoid arthritis. N Engl J Med. 376:652–662.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tanaka Y, Emoto K, Cai Z, Aoki T,
Schlichting D, Rooney T and Macias W: Efficacy and safety of
baricitinib in Japanese patients with active rheumatoid arthritis
receiving background methotrexate therapy: A 12-week, double-blind,
randomized placebo-controlled study. J Rheumatol. 43:504–511. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Smolen JS, Kremer JM, Gaich CL, DeLozier
AM, Schlichting DE, Xie L, Stoykov I, Rooney T, Bird P, Sánchez
Bursón JM, et al: Patient-reported outcomes from a randomised phase
III study of baricitinib in patients with rheumatoid arthritis and
an inadequate response to biological agents (RA-BEACON). Ann Rheum
Dis. 76:694–700. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leonard WJ and O'Shea JJ: Jaks and STATs:
Biological implications. Annu Rev Immunol. 16:293–322. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pelletier S, Gingras S, Funakoshi-Tago M,
Howell S and Ihle JN: Two domains of the erythropoietin receptor
are sufficient for Jak2 binding/activation and function. Mol Cell
Biol. 26:8527–8538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kawashiri SY, Kawakami A, Yamasaki S,
Imazato T, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Nakamura H,
Ida H, et al: Effects of the anti-interleukin-6 receptor antibody,
tocilizumab, on serum lipid levels in patients with rheumatoid
arthritis. Rheumatol Int. 31:451–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Souto A, Salgado E, Maneiro JR, Mera A,
Carmona L and Gómez-Reino JJ: Lipid profile changes in patients
with chronic inflammatory arthritis treated with biologic agents
and tofacitinib in randomized clinical trials: A systematic review
and meta-analysis. Arthritis Rheumatol. 67:117–127. 2015.
View Article : Google Scholar : PubMed/NCBI
|
